首页 | 本学科首页   官方微博 | 高级检索  
     


Enzalutamide in Japanese patients with chemotherapy‐naïve,metastatic castration‐resistant prostate cancer: A post‐hoc analysis of the placebo‐controlled PREVAIL trial
Authors:Go Kimura  Junji Yonese  Takashi Fukagai  Tomomi Kamba  Kazuo Nishimura  Masahiro Nozawa  Hank Mansbach  Ad Theeuwes  Tomasz M Beer  Bertrand Tombal  Takeshi Ueda
Affiliation:1. Department of Urology, Nippon Medical School, Tokyo, Japan;2. Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;3. Department of Urology, Showa University Koto Toyosu Hospital, Tokyo, Japan;4. Department of Urology, Kyoto University Hospital, Kyoto, Japan;5. Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan;6. Department of Urology, Kinki University Faculty of Medicine, Higashiosaka City, Osaka, Japan;7. Clinical Development, Medivation, San Francisco, California, USA;8. Biostatistics, Astellas Pharma Global Development, Leiden, The Netherlands;9. OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA;10. Division of Urology, Cliniques Universitaires Saint‐Luc, Brussels, Belgium;11. Division of Urology, Chiba Cancer Center, Chiba, Japan
Abstract:
Keywords:antineoplastic agents  disease‐free survival  Japan  MDV 3100  prostatic neoplasms, castration‐resistant
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号